- Khiron reaches more than 3,500 medical cannabis prescriptions
filled
- Medical cannabis prescriptions increased by over 450% in Q3,
compared to Q2 of 2020
- Khiron's clinics exceeded 9,000 monthly patient consultations
in September, marking a return to pre-pandemic monthly levels,
supported by the launch of telehealth consultations
- Khiron was declared a National Strategic Project by the
Government of Colombia in
September, accelerating its ability to register and introduce new
SKUs in the medical cannabis and consumer-packaged goods
categories
- Khiron became the first company to sell medical cannabis in
Peru, introducing its new CBD
brand AlexinTM, sold under its previously announced
agreement with Farmacia Universal, the largest compounding pharmacy
in Peru
- In September, the Company signed partnerships with 15 clinics
and health centres in Colombia,
extending education and sales reach further across the country
- As the exclusive LatAm provider, Khiron began sales of medical
products to patients participating in Project Twenty21 in the UK,
the largest medical cannabis patient registry in Europe
- Medical cannabis e-learning platform introduced in UK in
partnership with the Medical Cannabis Clinicians Society, an
independent, clinician-led organization sharing guidance to lead
the medical cannabis conversation in the UK
- Khiron's e-learning program accelerates medical cannabis
knowledge for doctors participating in Project Twenty21, which now
includes over 9,000 registrants
TORONTO, Oct. 9, 2020 /CNW/ - Khiron Life Sciences Corp.
("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF),
(Frankfurt: A2JMZC), a vertically
integrated cannabis leader with core operations in Latin America and Europe, is pleased to provide a corporate
update on its global medical cannabis operations, including
accelerating growth of 450% in its Colombian medical cannabis
prescriptions, first sales in the UK, and entry into the Peruvian
market.
"We have been saying for some time that we are in the execution
phase of our business strategy. Measurable developments over recent
weeks substantiate our approach and importantly, the ability of our
team to execute on the plan. Despite the impact of the global
pandemic, our medical cannabis sales are seeing accelerated growth
in Colombia, with more than 3,500
prescriptions now filled. In addition, we supplied medical
cannabis to Project Twenty21 participants in the UK, and began
medical cannabis sales in Peru.
Further, as a result of our timely adoption of technology-based
solutions, clinic consultations returned to pre-pandemic monthly
levels in September," comments Alvaro
Torres, Khiron CEO and Director.
About Khiron Life Sciences Corp.
Khiron is a
vertically integrated medical and CPG cannabis company with core
operations in Latin America, and
operational activity in Europe and
North America. Khiron is the leading cannabis company in
Colombia and the first company
licensed in Colombia for the
cultivation, production, domestic distribution and sales, and
international export of both low and high THC medical cannabis
products. The Company has filled medical cannabis prescriptions in
Peru and has a presence in
Mexico, Uruguay, UK, Spain and also in Germany, where it is positioned to begin sales
of medical cannabis.
Leveraging its first-mover advantage and patient-oriented
approach, Khiron combines global scientific expertise, product
innovation, agricultural infrastructure, wholly-owned medical
clinics, and online doctor education programs to drive prescription
and brand loyalty to address priority medical conditions. Its
Wellbeing unit launched the first branded CBD skincare brand in
Colombia, with KuidaTM
now marketed in multiple jurisdictions in Latin America, the US and UK. The Company is
led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and
diverse executive team and Board of Directors.
Visit Khiron online at investors.khiron.ca and on Instagram
@khironlife.
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment on
analyses, expectations or statements made by third-parties in
respect of Khiron, its securities, or financial or operating
results (as applicable). Although Khiron believes that the
expectations reflected in forward-looking statements in this press
release are reasonable, such forward-looking statement has been
based on expectations, factors and assumptions concerning future
events which may prove to be inaccurate and are subject to numerous
risks and uncertainties, certain of which are beyond Khiron's
control, including the risk factors discussed in Khiron's Annual
Information Form which is available on Khiron's SEDAR profile at
www.sedar.com. The forward-looking information contained in this
press release is expressly qualified by this cautionary statement
and is made as of the date hereof. Khiron disclaims any intention
and has no obligation or responsibility, except as required by law,
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/khiron-corporate-update-company-reports-accelerated-increase-in-medical-cannabis-prescriptions-301149149.html
SOURCE Khiron Life Sciences Corp.